Benjamin Ebert

Oct 23, 2024 | nature.com | Benjamin Ebert

Correction to: Nature Medicine https://doi.org/10.1038/nm.4047, published online 15 February 2016. In the version of the article initially published, the micrograph labeled #8840 in Supplementary Fig. 6a was a duplicate of the micrograph labelled #8900, also shown in the figure. A revised Supplementary information file accompanies the online version of this notice and includes the corrected #8840 micrograph.

Sep 6, 2024 | healio.com | Mark Leiser |Mindy Valcarcel |Benjamin Ebert

You've successfully added Leukemia to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Laurie H. Glimcher, MD, announced her intention to step down as president and CEO of Dana-Farber Cancer Institute on Oct. 1.

Apr 28, 2024 | nature.com | Radosław Nowak |Benjamin Ebert

AbstractTargeted protein degradation refers to the use of small molecules to induce the selective degradation of proteins. In its most common form, this degradation is achieved through ligand-mediated neo-interactions between ubiquitin E3 ligases — the principal waste disposal machines of a cell — and the protein targets of interest, resulting in ubiquitylation and subsequent proteasomal degradation.

Jan 2, 2024 | jci.org | Hojong Yoon |Justine C. Rutter |Yen-Der Li |Benjamin Ebert

Pharmacological manipulation of the ubiquitin-proteasome systemThe majority of induced protein degradation engages the ubiquitin-proteasome system. This pathway leverages a posttranslational modification – the covalent attachment of ubiquitin to a substrate protein through the coordinated, sequential activity of three classes of enzymes (22). First, an E1 ubiquitin-activating enzyme utilizes ATP to adenylate ubiquitin and establish a thioester bond between ubiquitin and the E1 enzyme.

Dec 18, 2023 | nature.com | Tuan Nguyen |Katherine A. Donovan |Santosh K. Chaudhary |Ananthan Sadagopan |David R. Liu |Benjamin Ebert

AbstractProteolysis-targeting chimeras (PROTACs) are molecules that induce proximity between target proteins and E3 ligases triggering target protein degradation. Pomalidomide, a widely used E3 ligase recruiter in PROTACs, can independently degrade other proteins, including zinc-finger (ZF) proteins, with vital roles in health and disease.